Chinese guidelines for the diagnosis and treatment of allergic asthma (the second edition, 2025).
10.3760/cma.j.cn112138-20250713-00407
- Collective Name:Chinese Society of Allergy;Chinese Society for the Promotion of Human Health Science and Technology Committee on Chronic Airway Disease
- Publication Type:Journal Article
- MeSH:
Humans;
Asthma/therapy*;
China;
Allergens;
Practice Guidelines as Topic;
Evidence-Based Medicine
- From:
Chinese Journal of Internal Medicine
2025;64(11):1026-1054
- CountryChina
- Language:Chinese
-
Abstract:
Allergic asthma, a major phenotype of bronchial asthma, shares similarities and differences with non-allergic asthma in its pathogenesis, clinical manifestations, diagnostic approach and criteria, and intervention strategies. The "Chinese guidelines for the diagnosis and treatment of allergic asthma (2019, the first edition)" established a framework for standardizing clinical practice relating to this condition in China. Based on the first edition, this guideline combines recent research progress and novel clinical evidence to supplement and revise the epidemiology, pathogenesis, common allergens, clinical manifestations, diagnostic techniques and standards, treatment and prevention principles of allergic asthma. Key amendments were made to the definition and underlying mechanisms, allergen detection techniques, and endotype assessment. Based on the current landscape of allergic asthma management in China, the updated guidelines provide tailored diagnostic and therapeutic recommendations, especially for allergen-specific immunotherapy, biologic-targeted therapies, and tertiary prevention strategies. A total of 14 evidence-based recommendations are proposed, serving as a clinical reference (guiding document) for optimizing the diagnosis, treatment, and long-term management of allergic asthma in China.
